Hypersensitivity to Aurora Kinase Inhibitors in Cells Resistant against Platinum- Containing Anticancer Agents

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)


Volume 15, 10 Issues, 2015


Download PDF Flyer




Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 29th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.469
5 - Year: 2.974

Hypersensitivity to Aurora Kinase Inhibitors in Cells Resistant against Platinum- Containing Anticancer Agents



Anti-Cancer Agents in Medicinal Chemistry, 14(7): 1042-1050.

Author(s): Masaki Akiyama, Hiroto Izumi, Ke-Yong Wang, Takahiro Yamaguchi, Akihiro Kuma, Noriaki Kitamura, Yoshikazu Harada, Ryoichi Oya, Koji Yamaguchi, Yoshiko Iwai and Kimitoshi Kohno.

Affiliation: President Laboratory, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan.

Abstract

The aurora kinases are serine/threonine kinases that are essential for mitosis and contribute to tumorigenesis. Therefore, aurora kinases hold promise for molecularly targeted therapy. In the present study, we demonstrated that aurora B kinase (AURKB) is overexpressed in both cisplatin- and oxaliplatin-resistant cells. Downregulation of AURKB sensitized cells to both cisplatin and oxaliplatin, but not to paclitaxel, 5-FU or hydrogen peroxide. Interestingly, we found that both cisplatin- and oxaliplatin-resistant cells were hypersensitive to the AURKB specific inhibitors, AZD1152 HQPA and ZM447439, suggesting that both cisplatin- and oxaliplatinresistant cells develop an addiction to AURKB. These data provide evidence that aurora kinase inhibitors can overcome both cisplatin and oxaliplatin resistance. Therefore, AURKB inhibitors could offer potential benefits if used after first-line platinum-based chemotherapy.

Keywords:

Acquired drug resistance, addiction, AURKB, AURKB inhibitor, cisplatin, oxaliplatin.



Purchase Online Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 14
Issue Number: 7
First Page: 1042
Last Page: 1050
Page Count: 9
DOI: 10.2174/1871520614666140207154351
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2015 Bentham Science